Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

ABT-199 treatment

YJ Yuhao Jiao
JD Joanne E. Davis
JR Jai Rautela
EC Emma M. Carrington
ML Mandy J. Ludford-Menting
WG Wilford Goh
RD Rebecca B. Delconte
FS Fernando Souza-Fonseca-Guimaraes
RK Rachel Koldej
DG Daniel Gray
DH David Huang
BK Ben T. Kile
AL Andrew M. Lew
DR David S. Ritchie
NH Nicholas D. Huntington
request Request a Protocol
ask Ask a question
Favorite

The molecular formula of ABT-199 is C45H50ClN7O7S, and the molecular weight is 868.4 g/mol. ABT-199 inhibits BCL-2 as a BH-3 mimetic. Mice were treated with ABT-199 (Active Biochem) or vehicle control by oral gavage (100 mg/kg) on two consecutive days immediately prior to TBI and alloSCT. ABT-199 was formulated in 60% phosal® 50 PG (standardized phosphatidylcholine concentrate with at least 50% PC and propylene glycol; Phospholipid GmbH, Cologne, Germany), 30% polyethylene glycol (PEG) 400, and 10% ethanol.

Copyright and License information: ADMC Associazione Differenziamento e Morte Cellulare ©2018

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A